HKSE:02607 (China)
Â
Class H
HK$
11.4
-0.46 (-3.88%)
Jun 30
Business Description
Shanghai Pharmaceuticals Holding Co Ltd
ISIN : CNE1000012B3
Share Class Description:
HKSE:02607: Class HTotal Employee Number:
49,608Compare
Compare
Traded in other countries / regions
601607.China02607.Hong KongS1R.GermanySHPMF.USA Index Membership
Hong Kong Stock Connect IPO Date
2011-05-20Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.77 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | 4.59 | |||||
Interest Coverage | 6.07 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.09 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.7 | |||||
3-Year EBITDA Growth Rate | 2 | |||||
3-Year EPS without NRI Growth Rate | -13.4 | |||||
3-Year FCF Growth Rate | 20.4 | |||||
3-Year Book Growth Rate | 4.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.37 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.45 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.52 | |||||
9-Day RSI | 35.85 | |||||
14-Day RSI | 40.1 | |||||
3-1 Month Momentum % | -1.73 | |||||
12-1 Month Momentum % | -2.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.34 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 58.99 | |||||
Days Sales Outstanding | 109.97 | |||||
Days Payable | 88.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.79 | |||||
Dividend Payout Ratio | 0.23 | |||||
3-Year Dividend Growth Rate | -0.8 | |||||
Forward Dividend Yield % | 4.53 | |||||
5-Year Yield-on-Cost % | 3.98 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -3.09 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 10.85 | |||||
Operating Margin % | 3.35 | |||||
Net Margin % | 2.02 | |||||
EBITDA Margin % | 4.05 | |||||
FCF Margin % | 1.73 | |||||
OCF Margin % | 2.52 | |||||
ROE % | 7.7 | |||||
ROA % | 2.48 | |||||
ROIC % | 6.34 | |||||
3-Year ROIIC % | -2.04 | |||||
ROC (Joel Greenblatt) % | 18.8 | |||||
ROCE % | 11.97 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 6.61 | |||||
Forward PE Ratio | 7.01 | |||||
PE Ratio without NRI | 5.79 | |||||
Shiller PE Ratio | 10.46 | |||||
Price-to-Owner-Earnings | 15.88 | |||||
PS Ratio | 0.19 | |||||
PB Ratio | 0.74 | |||||
Price-to-Tangible-Book | 1.02 | |||||
Price-to-Free-Cash-Flow | 11.05 | |||||
Price-to-Operating-Cash-Flow | 7.61 | |||||
EV-to-EBIT | 6.83 | |||||
EV-to-Forward-EBIT | 9.9 | |||||
EV-to-EBITDA | 6.83 | |||||
EV-to-Forward-EBITDA | 7.77 | |||||
EV-to-Revenue | 0.28 | |||||
EV-to-Forward-Revenue | 0.27 | |||||
EV-to-FCF | 16.02 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Projected-FCF | 0.68 | |||||
Price-to-Median-PS-Value | 0.68 | |||||
Price-to-Graham-Number | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 2.31 | |||||
Earnings Yield (Greenblatt) % | 14.64 | |||||
FCF Yield % | 9.16 | |||||
Forward Rate of Return (Yacktman) % | -0.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Pharmaceuticals Holding Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 318,871.898 | ||
| EPS (TTM) (HK$) | 1.724 | ||
| Beta | 0.5205 | ||
| 3-Year Sharpe Ratio | -0.6 | ||
| 3-Year Sortino Ratio | -0.86 | ||
| Volatility % | 14.01 | ||
| 14-Day RSI | 40.1 | ||
| 14-Day ATR (HK$) | 0.295406 | ||
| 20-Day SMA (HK$) | 11.742 | ||
| 12-1 Month Momentum % | -2.99 | ||
| 52-Week Range (HK$) | 10.96 - 13.12 | ||
| Shares Outstanding (Mil) | 3,708.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Pharmaceuticals Holding Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Pharmaceuticals Holding Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-30 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 58 days | ||
| HKD 0.404770 Cash Dividend | 2026-07-14 | In 13 days | ||
| General meeting for 2025 | 2026-06-25 10:20 | 11.90 (+0.42%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 11.70 (+0.52%) | ||
| Annual report for 2025 | 2026-03-31 | 11.57 (+1.76%) | ||
| HKD 0.132150 Cash Dividend | 2025-12-29 | 11.73 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-10-30 | 12.25 (-0.81%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 12.42 (-2.59%) | ||
| HKD 0.316970 Cash Dividend | 2025-07-16 | 12.26 (-0.81%) |
Show
Entries
Shanghai Pharmaceuticals Holding Co Ltd Frequently Asked Questions
What is Shanghai Pharmaceuticals Holding Co Ltd(HKSE:02607)'s stock price today?
The current price of HKSE:02607 is HK$11.40. The 52 week high of HKSE:02607 is HK$13.12 and 52 week low is HK$10.96.
When is next earnings date of Shanghai Pharmaceuticals Holding Co Ltd(HKSE:02607)?
The next earnings date of Shanghai Pharmaceuticals Holding Co Ltd(HKSE:02607) is 2026-08-28 Est..
Does Shanghai Pharmaceuticals Holding Co Ltd(HKSE:02607) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Pharmaceuticals Holding Co Ltd(HKSE:02607) is 3.79% (As of Today), Highest Dividend Payout Ratio of Shanghai Pharmaceuticals Holding Co Ltd(HKSE:02607) was 0.63. The lowest was 0.23. And the median was 0.34. The  Forward Dividend Yield % of Shanghai Pharmaceuticals Holding Co Ltd(HKSE:02607) is 4.53%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Shanghai Pharmaceuticals Holding Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers